bizSanDiego the business of san diego county

Metabasis Announces Conference Call and Live Webcast to Discuss Third Quarter 2008 Financial Results

Friday, October 10, 2008

By

SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, (Nasdaq:MBRX) will announce its third quarter 2008 earnings results on Thursday, November 6, 2008, after markets close. Following the earnings release, Metabasis will hold a conference call and live webcast at 4:30 p.m. Eastern Time to discuss financial and other business results. Dr. Paul Laikind, president and chief executive officer and Mr. Dan Milles, senior director of finance, will participate in the call. Dr. Mark Erion, executive vice president of research and development and chief scientific officer, will also be available to answer questions.

The conference call may be accessed by dialing 866-356-3093 for domestic callers and 617-597-5381 for international callers. Please specify to the operator “Metabasis” when asked for a passcode. The conference call will be webcast live on the Metabasis website at www.mbasis.com, under the Investors section, and will be archived there for 30 days following the call. Please connect to Metabasis’ website several minutes prior to the start of the call to ensure adequate time for any software download that may be necessary.

About Metabasis (www.mbasis.com):

Metabasis is a biopharmaceutical company using its proprietary technologies, scientific expertise and unique capabilities for targeting the liver and liver pathways to develop novel therapies to treat metabolic and other diseases. The Company has established a broad pipeline of product candidates and advanced research programs targeting large markets with significant unmet needs. Metabasis' core area of focus is on the discovery and development of drug candidates to treat metabolic diseases such as hyperlipidemia and diabetes, among others. Although not a core focus of the Company, Metabasis has also discovered and developed drug candidates indicated for the treatment of liver diseases such as hepatitis and primary liver cancer, which it now intends to license or partner. All product candidates were developed internally using proprietary technologies.

Source: BUSINESS WIRE